RLYB · Rallybio Corporation

Current Thesis

Rallybio is a special-situations reverse-merger shell, not a narrative-momentum vehicle. On 2026-06-01 it agreed to acquire private oncology developer Avenzo Therapeutics in an all-stock reverse merger alongside a $215M oversubscribed concurrent PIPE; the combined company rebrands Avenzo Therapeutics and is slated to trade as AVZO, closing Q4 2026. Shares spiked intraday into the $16.56–$18.54 zone on announcement and have since drifted back toward the mid-$14s by 2026-06-07 the round-trip says the deal pop was the entire event, with no follow-through leg. The go-forward oncology value accrues to Avenzo and PIPE holders, who will own ~97.2% of the combined company. Pre-close Rallybio holders keep a cash distribution of substantially all net cash, one non-transferable CVR per share, and a thin ~2.8% equity stub (implied Rallybio valuation just $15M against Avenzo's $300M). There is no accelerating narrative leg available to a fresh buyer here; this is sum-of-parts and merger-arb work, outside the momentum mandate.

Bull Case

• Cash floor with a defined return path (2026-06-01). Rallybio was a winding-down shell it executed a 1-for-8 reverse split on 2026-02-06 purely to hold Nasdaq listing compliance. The deal converts a stranded cash pile (~$46.8M cash + marketable securities at 3/31/26; deal docs assume substantially all of it is distributed, leaving ~$0 Rallybio net cash at close) into a defined cash distribution to pre-close holders, so the downside floor is largely the cash itself.
• Free CVR optionality. One CVR per share entitles holders to a pro-rata share of net proceeds from legacy-asset dispositions plus cash from the Recursion Pharmaceuticals membership-interest purchase agreement (REV102 program). Zero-cost lottery ticket; pays nothing if no proceeds are realized.
• Avenzo is a funded clinical asset, not an empty SPAC. Four-program oncology pipeline: AVZO-021 (selective CDK2 inhibitor — ASCO 2026-06-01 showed 5.3-month median PFS in heavily-pretreated HR+/HER2− breast at a median of 4 prior lines, with clean GI/heme tolerability), AVZO-023 (CDK4), AVZO-1418 (EGFR/HER3 bispecific ADC), AVZO-103 (Nectin4/TROP2 bispecific ADC). The $215M PIPE funds the combined company into late 2028.
• Institutional validation of the target. The concurrent placement drew Blackstone Multi-Asset Investing, accounts advised by T. Rowe Price Investment Management, Vivo Capital, Affinity Asset Advisors, and ADAR1 Capital Management alongside a leading mutual fund and a life-sciences fund a syndicate that lowers financing-fall-through risk and signals real conviction in the Avenzo pipeline.

Bear Case

• The move already happened. The +19% announcement spike on 2026-06-01 was the event; by 2026-06-07 the stock has faded back toward its pre-announcement mid-$14s. Buying now is chasing a priced-in M&A pop with no second leg.
• Legacy holders own almost nothing of the future. Pre-deal Rallybio shareholders end up with ~2.8% of the combined company implied equity value of just $15M against Avenzo's $300M and a $215M raise (~$530M pro-forma equity story). The oncology narrative does not accrue to a current RLYB buyer in any meaningful size.
• The 2.8% is struck after the cash leaves. The ownership split is calculated assuming ~$0 Rallybio net cash at close, because the cash is distributed out first. The stub is a sliver of operating company, not a sliver of company-plus-cash.
• Deal-break, dilution, and timeline risk into Q4 2026. Closing requires approval by both shareholder bases, S-4 registration effectiveness, Nasdaq listing approval for the combined entity, and completion of the $215M financing. The plaintiff-firm "investigation" boilerplate (Brodsky & Smith, 2026-06-02) is routine merger noise but flags the months-long legal grind. Capital parked here is dead money until close.
• Wrong tool for this book. This is event-driven merger-arb and discount-to-distribution value work idiosyncratic, deal-spread-dominated, and explicitly outside a narrative-momentum mandate.

Setup & Price Structure

• Price action: vertical one-day gap on deal news into the $16.56–$18.54 range (2026-06-01), now retraced toward the mid-$14s (~$14.46–$14.64 area, 2026-06-07). The spike has substantially round-tripped an event candle being absorbed, not a multi-week base-and-breakout.
• Float/structure: low float following the 1-for-8 reverse split (2026-02-06). No trend, no rising moving-average structure to lean on; the gap is the news, and the fade is the market repricing toward intrinsic distribution value.
• Valuation lens (sum-of-parts, the only honest frame): legacy value ≈ net-cash distribution (substantially all of ~$46.8M cash+securities, before deal/wind-down costs) + the ~$15M Avenzo stub valuation + an uncertain CVR. At current levels the residual arbitrage edge is thin and carries genuine deal-break tail risk into a Q4 close.
• Momentum read: event-driven, mean-reverting profile. The announcement RSI spike has already cooled as price retraced; there is no momentum signature for a trend-follower to engage.

Catalyst Calendar (next 30 days)

• No dated, tradable catalysts inside the 2026-06-07 → 2026-07-07 window. The binary (deal announcement + ASCO AVZO-021 data) already printed on 2026-06-01.
• S-4 registration effectiveness pending, no date set (est. Q3 2026). Registration statement expected to be filed/amended ahead of the shareholder vote; effectiveness is a gating step, not yet scheduled.
• Dual shareholder votes + cash-distribution record date pending (est. Q3–Q4 2026). Both Rallybio and Avenzo shareholder approvals required; record date for the legacy cash distribution to be set in proxy materials.
• Merger close / AVZO Nasdaq listing ~Q4 2026 (est.). Far outside the 30-day window; this is the terminal event, contingent on the $215M financing completing.
• No PDUFA, no earnings print, and no clinical readout dated within the next 30 days.

What Would Change Our Mind

• Merger termination. If the deal breaks and RLYB reverts to a pure cash shell, a clean discount-to-cash arbitrage could open up a different, simpler setup worth re-underwriting from scratch.
• A clear discount to net-cash distribution value. If shares trade demonstrably below the per-share value of substantially-all-net-cash (against ~$46.8M cash+securities, ~$37.5M assumed net) the residual arb becomes attractive on its own terms rather than as a momentum trade.
• Material CVR disclosure. Concrete terms on the Recursion/REV102 disposition or other legacy-asset sales that put a credible, sizeable number on the CVR would change the sum-of-parts math.
• The oncology story belongs to AVZO post-close. Anyone who wants the CDK2/CDK4/ADC narrative should engage the listed AVZO entity after close on a fresh setup, not the RLYB shell now. The dossier should be re-tagged and relinked to AVZO once the merger completes.

Correlation Notes

• Idiosyncratic special situation, near-zero index beta. Price is governed by the deal spread and the cash-distribution math, not by SPY or biotech-sector flows; XBI sensitivity is minimal while the merger is pending.
• Merger-arb correlation, not sector correlation. Behaves like a deal spread sensitive to biotech financing conditions and the risk appetite of PIPE backers (Blackstone, T. Rowe Price, Vivo, ADAR1, Affinity), and to headline deal-break risk, rather than to the broad tape.
• CDK / ADC read-through accrues to AVZO, not RLYB. Avenzo's CDK2/CDK4 and Nectin4/TROP2/EGFR-HER3 ADC programs sit in the competitive precision-oncology set (selective CDK inhibitors, next-gen ADCs), but that read-through reaches a current RLYB holder only through the ~2.8% stub too thin to trade as a thematic proxy until the AVZO listing exists.
• Theme placement: special-situations / M&A-event cohort first, precision-oncology second. Right now the M&A structure dominates the tape; the oncology theme is dormant for this ticker until close.

Theme Status

The relevant momentum theme (precision-oncology / CDK-ADC) is MATURING in the broad market but DORMANT for this vehicle none of that narrative accrues to RLYB pre-close. As a standalone setup the name is event-spent: the catalyst fired, the spike faded, and the remaining path is a slow legal grind into a Q4 2026 close. The setup is a pass for a momentum book; the oncology engagement, if any, is AVZO on a fresh post-listing setup.